Table 1. Auxological and biochemical characteristics in participants.
| Parameters | Idiopathic GHD | Organic GHD | P valueb | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total (N = 131) | Male (n = 83) | Female (n = 48) | P valuea | Total (N = 32) | Male (n = 17) | Female (n = 15) | P valuea | ||
| CA, yr | 7.50 ± 2.91 | 7.57 ± 3.18 | 7.38 ± 2.40 | 0.926 | 9.72 ± 3.58 | 9.53 ± 3.51 | 9.93 ± 3.76 | 0.761 | 0.001 |
| BA, yr | 5.45 ± 2.92 | 5.51 ± 3.25 | 5.33 ± 2.30 | 0.698 | 7.24 ± 3.73 | 7.09 ± 3.29 | 7.47 ± 4.53 | 0.821 | 0.018 |
| CA-BA, yr | 1.89 ± 0.99 | 1.92 ± 1.04 | 1.83 ± 0.92 | 0.631 | 2.04 ± 1.28 | 2.18 ± 1.25 | 1.82 ± 1.37 | 0.520 | 0.530 |
| Ht SDS | −2.84 ± 0.75 | −2.77 ± 0.72 | −2.96 ± 0.80 | 0.232 | −2.21 ± 1.50 | −2.54 ± 1.33 | −1.83 ± 1.64 | 0.201 | 0.043 |
| Wt SDS | −1.95 ± 1.12 | −2.04 ± 0.94 | −1.80 ± 1.37 | 0.340 | −1.17 ± 1.49 | −1.57 ± 1.01 | −0.70 ± 1.82 | 0.129 | 0.011 |
| BMI SDS | −0.31 ± 1.22 | −0.49 ± 1.11 | 0.01 ± 1.35 | 0.055 | 0.06 ± 1.23 | −0.20 ± 0.85 | 0.35 ± 1.53 | 0.243 | 0.099 |
| MPH SDS | −0.75 ± 0.77 | −0.61 ± 0.70 | −0.98 ± 0.84 | 0.013 | 0.09 ± 0.59 | −0.06 ± 0.51 | 0.22 ± 0.64 | 0.243 | < 0.001 |
| PAH SDS | −1.81 ± 1.10 | −1.66 ± 1.07 | −2.10 ± 1.13 | 0.205 | −0.33 ± 2.02 | −0.20 ± 2.21 | −0.59 ± 1.87 | 0.770 | 0.031 |
| Prepubertalc | 44 (86.2) | 17 (85.0) | 27 (87.1) | 0.832 | 14 (82.4) | 7 (70.0) | 7 (100) | 0.110 | 0.693 |
| Ht SDS–MPH SDS | −2.04 ± 0.90 | −2.06 ± 0.83 | −2.01 ± 1.04 | 0.821 | −2.32 ± 0.94 | −2.28 ± 1.08 | −2.35 ± 0.84 | 0.862 | 0.179 |
| IGF-1 SDS | −0.71 ± 0.92 | −0.67 ± 0.90 | −0.78 ± 0.98 | 0.992 | −0.45 ± 2.78 | −0.03 ± 3.50 | −0.92 ± 1.79 | 1.000 | 0.045 |
| IGFBP-3 SDS | −0.44 ± 1.75 | −0.31 ± 1.54 | −0.70 ± 2.12 | 0.373 | −0.45 ± 3.03 | −0.51 ± 3.72 | −0.38 ± 1.92 | 0.306 | 0.270 |
| Peak GH level on GHST, μg/L | 6.47 ± 2.54 | 6.58 ± 2.46 | 6.28 ± 2.69 | 0.683 | 2.22 ± 2.42 | 2.26 ± 2.74 | 2.18 ± 2.09 | 0.925 | < 0.001 |
| Initial GH dose, mg/kg/week | 0.23 ± 0.05 | 0.23 ± 0.05 | 0.23 ± 0.04 | 0.494 | 0.20 ± 0.07 | 0.23 ± 0.06 | 0.17 ± 0.07 | 0.017 | 0.026 |
| Mean GH dose during 3 yr of GH treatment, mg/kg/week | 0.23 ± 0.04 | 0.23 ± 0.04 | 0.23 ± 0.04 | 0.736 | 0.19 ± 0.06 | 0.22 ± 0.04 | 0.17 ± 0.07 | 0.034 | 0.001 |
Values are presented as number (%) or mean ± standard deviation.
GHD = growth hormone deficiency, CA = chronological age, BA = bone age, Ht = height, SDS = standard deviation score, Wt = weight, BMI = body mass index, MPH = mid-parental height, PAH = predicted adult height, IGF-1 = insulin like growth factor-1, IGFBP-3 = insulin like growth factor-binding protein-3, GH = growth hormone, GHST = growth hormone stimulation test.
P values are calculated with independent t-test or Wilcoxon rank sum test: amale vs. female; bIGHD vs. OGHD.
cThis variable was analyzed from only available participants: IGHD (n = 51) and OGHD (n = 17).